<DOC>
	<DOCNO>NCT00424528</DOCNO>
	<brief_summary>The purpose study evaluate compare efficacy arformoterol twice day tiotropium day ( dose sequentially ) versus tiotropium day alone subject Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Safety Study Arformoterol/Tiotropium Combination Versus Either Therapy Alone Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This study multicenter , randomize , modified-blind , double-dummy two-week parallel-group efficacy safety study arformoterol tartrate inhalation solution twice daily , tiotropium inhalation powder daily arformoterol tartrate inhalation solution twice daily tiotropium inhalation powder daily ( dose sequentially ) subject COPD . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female subject must least 45 year old time consent . Subjects must preestablished primary clinical diagnosis COPD . Subjects must baseline FEV1 ≤65 % predict normal value Visit 1 . Subjects must FEV1 ≥ 0.70L Visit 1 . Subjects FEV1/forced vital capacity ( FVC ) ratio ≤70 % Visit 1 . Subjects ³15 packyear smoke history baseline breathlessness severity grade ³2 ( Modified Medical Research Council [ MMRC ] Dyspnea Scale Score ) Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD include chronic bronchitis emphysema</keyword>
</DOC>